The Specimen Accessioning Core (SAC) provides a centralized resource for the collection and processing of blood, bone marrow, and tumor cell samples from patients with malignancies as well as samples from normal volunteer donors. This Core was initially established in order to facilitate and support the ongoing laboratory and clinical research within the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC). In addition, the SAC provides rigorous quality assurance and quality control for the processing and storage of clinical samples. Thus, the specific aims of this Core are to: 1) Centralize accessioning of patient specimens, 2) Process patient specimens and tissue samples utilizing good laboratory practices (GLP) procedures, 3) Store specimens in a well-controlled and monitored environment in order to ensure sample integrity, 4) Fairly and equitably distribute accessioned samples to investigators with IRB-approved research questions. 5) Maintain a secure relational data base that includes detailed information on the handling and processing of the samples along with pertinent clinical and demographic data that correlate to the specimen. 6) Provide expertise and support to investigators in the planning of sample collection for the development of correlative biologic tests for clinical trials and for pharmacokinetic/pharmacodynamic analysis and, 7) Provide a mechanism to ensure that informed consent is provided and subjects are maximally protected when volunteering to donate tissues for ongoing and future research by maintaining an active IRB-approved clinical trial (currently RPN#00-01-27-09, Tissue and Cell Procurement Protocol) that identified the research nature of the bank and assures HIPAA-compliances. Lay: The Specimen Accessioning Core laboratory processes samples including blood, urine and bone marrow from patients treated with a variety of new anti cancer drugs in order to test the samples for the effectiveness of these new anti-cancer drugs and to determine how these drugs are metabolized by the patients. The Specimen Accessioning Core laboratory also processes and banks a variety of tumors from patients with hematologic (blood) cancers and makes the cancer cells available to investigators within the cancer center for study in the laboratory.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-51
Application #
8661013
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
51
Fiscal Year
2014
Total Cost
$91,432
Indirect Cost
$35,107
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663
Boudadi, Karim; Suzman, Daniel L; Anagnostou, Valsamo et al. (2018) Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget 9:28561-28571
Dean, Lorraine T; Gehlert, Sarah; Neuhouser, Marian L et al. (2018) Social factors matter in cancer risk and survivorship. Cancer Causes Control 29:611-618
Yuan, Ming; Da Silva, Ana Cristina A L; Arnold, Antje et al. (2018) MicroRNA (miR) 125b regulates cell growth and invasion in pediatric low grade glioma. Sci Rep 8:12506
Jacobs, Michael A; Macura, Katarzyna J; Zaheer, Atif et al. (2018) Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. Acad Radiol 25:1405-1414
Annesley, Colleen E; Rabik, Cara; Duffield, Amy S et al. (2018) Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. Oncotarget 9:35313-35326
Liu, Tao; Ivaturi, Vijay; Sabato, Philip et al. (2018) Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship. Clin Transl Sci 11:435-443

Showing the most recent 10 out of 2393 publications